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Abstract 
Background: Recent research indicates that long non-coding RNAs (lncRNA) represent a new 
family of RNAs that is of fundamental importance for controlling transcription and translation. 
Thereby, there is increasing evidence that lncRNAs are also important in tumourigenesis. Thereby 
valid expression profiling using quantitative PCR requires suitable, stably expressed normalisers to 
achieve reliable and reproducible data. However, no systematic analysis of suitable references in 
lncRNA studies in human glioma has been performed yet.  
Methods: In this study, we investigated 90 lncRNAs in 30 tissue specimen for the expression 
stability in human diffuse astrocytoma (WHO-Grade II), anaplastic astrocytoma (WHO-Grade III) 
and glioblastoma (WHO-Grade IV) both alone as well as in comparison with normal white matter. 
Our identification procedure included a rigorous bioinformatical selection process that resulted in 
the inclusion of only highly abundant, equally expressed lncRNAs for further analysis. Additionally, 
lncRNAs were classified according to their stability value using the NormFinder algorithm.  
Results: We identified 24 appropriate normalisers suitable for studies in diffuse astrocytoma, 22 
for studies in anaplastic astrocytoma and 12 for studies in glioblastoma. Comparing all three glioma 
entities 7 lncRNAs showed stable expression levels. Addition of normal brain tissue resulted in 
only 4 suitable lncRNAs.  
Conclusions: Our findings indicate that 4 lncRNAs (HOXA6as, H19 upstream conserved 1 and 2, 
Zfhx2as and BC200) are suitable as normalisers in glioma and normal brain. These lncRNAs may 
thus be regarded as universal references being applicable for the accurate normalisation of lncRNA 
expression profiling in various glioma (WHO-Grades II-IV) alone and in combination with brain 
tissue. This enables to perform valid longitudinal studies, e.g. of glioma before and after ma-
lignisation to identify changes of lncRNA expressions probably driving malignant transformation. 
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Introduction 
Long non-coding RNA (lncRNA) has recently 
been observed not being just by-product in the pro-
cess of transcription but being of significant im-
portance in transcriptional and translational control as 
well as during splicing, cell cycle, apoptosis, pluripo-
tency, reprogramming and imprinting [1-8]. This 
highlights a potential role of lncRNAs during tumour 
formation and progression. Nevertheless, only a mi-
nority of lncRNAs has so far been investigated and 
functionally annotated. [1, 9]. According to Ma et al. 
lncRNAs can be classified by (1) genomic location, (2) 








mechanisms and (4) targeting mechanisms [10]. One 
of the best studied processes being associated with 
lncRNAs is the X-chromosome inactivation: A single 
X-inactivation center (Xic) of about 100-500 kbps in 
length [11, 12] is necessary and sufficient for 
X-chromosome inactivation [11, 13]. Thereby, Xic 
contains a well characterised lncRNA: Xist (X-inactive 
specific transcript). This is a 17-20 kbps long RNA that 
tags the X-chromosome during early X-chromosome 
inactivation [11, 12]. Subsequently, only the 
X-chromosome that expresses Xist is inactivated [11, 
14-18]. It is obvious that disturbances in such power-
ful regulation mechanisms can propagate the devel-
opment of numerous human diseases. 
Especially in the context of tumourigenesis, dis-
tinct lncRNAs have been highlighted [19, 20]: 
HOTAIR (HOX antisense intergenic RNA) is a 
lncRNA being expressed in various cancers interact-
ing with PRC2 (Polycomb repressive complex 2) [21]. 
Studies have shown that HOTAIR is associated with 
motility, invasion, and metastatic potential in tu-
mours [22]. HOTTIP is another example of a lncRNA 
that is potentially associated with the differentiation 
status of cancer cells that may be regarded as a 
co-factor leading to genomic rearrangements in cancer 
[20, 23, 24]. In case of the antisense lncRNA ANRIL 
studies have shown that ANRIL is able to repress 
tumour suppressor loci and thus may promote cancer 
[25]. 
There is recent evidence, that lncRNAs may also 
play a crucial role in brain tumours [26-28]. Glioblas-
toma (GBM, WHO-Grade IV) represent not only the 
most frequent brain tumour entity of adults but also 
the most fatal one with a high risk of recurrence and a 
very dismal prognosis [29]. Thereby, primary and 
secondary GBMs can be distinguished: Whilst pri-
mary GBMs are tumours that originate de novo, sec-
ondary GBMs are tumours that derive from low-
er-grade gliomas, i.e. diffuse astrocytoma (DA, A II, 
WHO-Grade II) and anaplastic astrocytoma (AA, A 
III, WHO-Grade III) in a process of malignant trans-
formation [29-31].  
Especially by investigating changes in gliomas 
occurring during tumour progression, i.e. DA, AA, 
GBM, the selection of suitable references for expres-
sion profiling is a challenge. “Ideal” references are 
genes that do not show expression changes in all in-
vestigated tumour entities. They have to be identified 
and validated prior to quantitative data analysis for 
each tissue type under the desired experimental setup 
[32, 33]. As the stability and integrity of different RNA 
classes, e.g. mRNA, rRNA, miRNA, is highly variable 
[32-37] normalisers should ideally be composed of the 
same RNA class as the target RNAs to avoid compu-
tational errors by referring to different RNA classes. 
So far, there are no lncRNA normalisers for 
quantitative PCR (qPCR) data in human gliomas 
available. Moreover, the importance to use a combi-
nation of at least two or more validated reverences for 
proper evaluation of data has not yet been considered 
[34-37]. This problem is now solved by us. In this 
study, we investigate 90 different lncRNAs in parallel 
on human diffuse astrocytoma, anaplastic astrocyto-
ma, glioblastoma and normal white matter as 
“healthy”, unaffected brain tissue. We determined 
stably expressed lncRNAs using the NormFinder al-
gorithm for both each entity alone as well as in com-
bination and in comparison with normal brain tissue. 
This way, we were able to identify stably expressed 
lncRNAs suitable as universal normalisers in studies 
investigating astrocytoma of different WHO-Grade, 
enabling longitudinally designed studies of tumours 
before and after malignant transformation. 
Materials and Methods 
Sample collection 
For this study, we selected 30 different tissue 
specimen including five human diffuse astrocytoma 
(WHO-Grade II), five anaplastic astrocytoma 
(WHO-Grade III), and 15 glioblastoma (WHO-Grade 
IV) as well as 5 human occipital white matter speci-
mens as “healthy” brain tissue. 
Tumour samples were provided by the Brain 
Tumour Bank of the Center for Neuropathology. 
Written informed consent was obtained according to 
the guidelines of the local ethics committee. Surgical 
samples were fixed with 4% buffered formalin, paraf-
fin embedded, and subjected to routine histological 
stains: H&E (Haematoxylin and Eosin), EvG (Elastic 
van Gieson), PAS (Periodic acid-Schiff), Gomori silver 
stain and immunohistochemistry using antibodies 
against GFAP (glial fibrillary acidic protein, mono-
clonal mouse antibody, clone 6F2, Dako), MAP2 (mi-
crotubule-associated protein 2, clone HM.2, Sigma) 
and Ki67 (monoclonal mouse antibody, clone MIB1, 
Dako). Tumour samples were classified according to 
the WHO (world health organisation) classification of 
tumours of the central nervous system, 4th edition, 
2007 [29-31]. Determination of IDH1 (isocitrate dehy-
drogenase 1) mutations was performed using the py-
rosequencing technique as described previously [38]. 
MGMT promoter methylation was determined as 
described previously [39]. LOH1p/19q (loss of heter-
ozygousity of chromosome 1p and 19q) was detected 
as described previously [40]. Detailed information of 
patients can be found in Table 1. 




Table 1. Tumour sample collection. Listed are all tumour samples used in this study including patient age at surgery, sex, tumour entity 
according to WHO-Grade, localisation and molecular genetic features of tumours. MGMT status: 0: not methylated; 1: methylated; 2: 
partially methylated; 9: not analysed due to low amount of tissue; IDH1-mutation: 0: wt; 1: R132H, 2: R132G; 3: R132C; 9: not analysed 
due to low amount of tissue; LOH1p/19q: 0: no; 1: 1p; 2: 19q; 3: 1p19q; 4: loss of some markers of 1p; 5: loss of some markers of 19q; 6: 
loss of some markers of 1p/19q; 9: not analysed due to low amount of tissue. 
Sample Age at surgery [y] Sex Tumor Entity WHO-Grade Localisation of tumor MGMT status IDH1-mutation LOH1p/19q 
AII_1 34 f Diffuse astrocytoma II frontal left 1 3 0 
AII_2 34 m Diffuse astrocytoma II fronto-temporal right 1 1 2 
AII_3 34 m Diffuse astrocytoma II intraparenchymatous 0 9 0 
AII_4 39 f Diffuse astrocytoma II frontal right 2 2 0 
AII_5 28 f Diffuse astrocytoma II precentral right 1 9 2 
AIII_1 21 f Anaplastic astrocytoma III frontal right 1 1 0 
AIII_2 50 f Anaplastic astrocytoma III frontal right 0 0 0 
AIII_3 25 m Anaplastic astrocytoma III intraparenchymatous 1 2 0 
AIII_4 40 m Anaplastic astrocytoma III temporal left 1 1 0 
AIII_5 39 m Anaplastic astrocytoma III temporoparietal left 1 0 0 
GBM_1 49 f Glioblastoma IV frontal right 1 1 5 
GBM_2 45 f Glioblastoma IV frontal right 0 0 5 
GBM_3 41 m Glioblastoma IV frontal left 1 1 9 
GBM_4 43 m Glioblastoma IV temporal right 2 0 6 
GBM_5 54 m Glioblastoma IV intraparenchymatous 1 0 9 
GBM_6 50 m Glioblastoma IV temporoparietal left 0 0 2 
GBM_7 44 m Glioblastoma IV frontal left 1 1 9 
GBM_8 46 m Glioblastoma IV temporal right 0 0 9 
GBM_9 61 m Glioblastoma IV parietal left 0 0 0 
GBM_10 55 f Glioblastoma IV bifrontal 1 1 9 
GBM_11 45 m Glioblastoma IV frontal left 1 0 2 
GBM_12 72 f Glioblastoma IV temporal 1 0 0 
GBM_13 73 m Glioblastoma IV temporal left 1 0 5 
GBM_14 67 m Glioblastoma IV occipital right 0 0 0 
GBM_15 34 f Glioblastoma IV frontal left 1 0 2 
 
 
Table 2. Control sample collection. Listed are all control samples 
used in this study including age of patients, sex, post-mortem 
intervals (PMI), investigated brain region and cause of death. 
Sample Age [y] Sex PMI [h] Region Cause of death 
WM_1 63 m 18 Occipital white matter Cardiac arrest 
WM_2 75 m 27 Occipital white matter Cardiac arrest 
WM_3 77 f 20 Occipital white matter Cardiac arrest 
WM_4 53 m 22 Occipital white matter Cardiac arrest 
WM_5 55 f 14 Occipital white matter Cardiac arrest 
 
 
Human control tissue was provided by the 
Neurobiobank Munich (NBM). All investigated cases 
were collected and clinically as well as neuropatho-
logically characterized according to the NBM stand-
ard protocols established by BrainNet Europe and 
BrainNet Germany. Patients did not show any neu-
rological or psychiatric disorders. Written informed 
consent was obtained according to the guidelines of 
the local ethics committee. Detailed information of 
selected cases can be found in Table 2. 
Extraction of RNA 
Representative H&E stained slides of FFPE tu-
mour samples were prepared and solid, viable tu-
mour consisting of at least 90% tumour cells was mi-
croscopically identified. RNA extraction was per-
formed on distinct, micro-dissected tumour regions. 
In case of normal brain tissue, subcortical, occip-
ital white matter was marked on H&E stained slides 
and isolation of distinct regions was performed simi-
lar to tumour samples. Extraction of RNA was per-
formed using the RNeasy FFPE Kit (Qiagen) accord-
ing to the manufacturer’s protocols. Quantity and 
quality of RNA was determined using a NanoDrop 
system determining the 260/280 nm absorbance ratio. 
In all cases the ratio was between 1.90 and 2.20. In 
order to avoid amplification bias we did not use 
pre-amplification of RNA but proceeded directly with 
subsequent analysis. 





verse transcription and quanti-
tative polymerase chain reaction 
(qPCR) 
Polyadenylation and reverse 
transcription reactions were per-
formed using the human LncProfiler 
qPCR Assay Kit (SBI). Equal amounts 
of RNA (750 ng) were used in the 
polyadenylation reaction. All proce-
dures were performed according to 
the optimised manufacturer’s proto-
cols. Quantification of lncRNAs was 
performed using the validated 
pre-designed qPCR primer library of 
the human lncProfiler qPCR Assay Kit 
(SBI) allowing the parallel investiga-
tion of 90 annotated lncRNAs that are 
listed in the lncRNA database. Quan-
titative PCR was performed on a 
LightCycler 480 II device (Roche) us-
ing the SensiFAST SYBR No-ROX Kit 
(Bioline) and standard protocols.  
Bioinformatical analysis 
Clustering of expression data 
was performed using Gene-E 
software (http://www.broadinstitute
.org/cancer/software/GENE-E/) and 
an un-supervised bi-hierarchical 
clustering algorithm based on 
pair-wise distance calculations. For 
the identification of stably expressed 
lncRNAs, cycle-threshold (Ct) values 
were used as basis for statistical 
analysis. To enhance reliability of 
data, only highly abundant lncRNAs 
(i.e. with Ct values < 30) were taken 
into consideration, lncRNAs with Ct 
values ≥ 30 were excluded due to low 
abundance and thus being not 
suitable as references. Furthermore, 
all lncRNAs that showed significant 
expression differences within 
different groups were excluded. For 
significance testing, GraphPad Prism 
software was used. We performed 
unpaired t-tests, p-values < 0.05 were 
considered as significant. Remaining 
lncRNAs were classified using the 
NormFinder algorithm taking both 
intra- and intergroup variations into 
consideration [41]. Only lncRNAs 
with stability values of < 0.1 were 
considered as appropriate. 
 
Figure 1. Bi-hierarchical clustering of all 90 investigated lncRNAs in 30 tissue specimen. We investi-
gated 5 diffuse astrocytomas (A II, DA, WHO-Grade II), 5 anaplastic astrocytomas (A III, AA, 
WHO-Grade III), and 15 glioblastomas (GBM, WHO-Grade IV) as well as 5 occipital white matter 
tissues (WM) as healthy control. There is a clear clustering of tumour entities visible. Blue: low Ct-value; 
red: high Ct-value. 
 





Each glioma entity shows different but distinct 
lncRNA profiles clearly separated from normal 
white matter 
The analysis of 90 lncRNAs in 5 diffuse astrocy-
tomas, 5 anaplastic astrocytomas, 15 glioblastomas 
and 5 normal white matter brain specimens show in 
an unsupervised bi-hierarchical clustering distinct 
lncRNA expression profiles (Figure 1): All diffuse 
astrocytomas build a distinct cluster that is flanked by 
anaplastic astrocytomas on one side. All anaplastic 
astrocytomas show another distinct cluster that is 
located between diffuse astrocytomas and glioblas-
tomas. All glioblastomas cluster together and are 
flanked by anaplastic astrocytomas. Furthermore, all 
normal white matter specimens show a distinct clus-
ter that is separated from all glioma clusters. The dif-
ferent clustering of lncRNA profiles emphasised that 
(1) lncRNA profiles of all tumour entities are indi-
vidual representing different molecular pathways 
being activated in the tumours, (2) there is a step-wise 
change of lncRNA profiles that is represented by the 
clustering of diffuse astrocytomas being situated next 
to anaplastic astrocytomas that are situated next to 
glioblastomas and (3) separation of lncRNA profiles 
of different glioma entities mirrors the need for nor-
malisers being equally expressed not only within one 
cluster but in all clusters to perform longitudinal 
studies on tumour specimen during tumour progres-
sion. 
Identification of reference lncRNAs in diffuse 
astrocytoma, anaplastic astrocytoma and gli-
oblastoma 
The conscious analysis of lncRNA expression 
data was performed in a step-wise bioinformatical 
approach. To get reliable references, only highly 
abundant lncRNAs were taken into consideration, i.e. 
lncRNAs with Ct values of ≥ 30 were excluded due to 
low abundance indicating not being suitable as nor-
malisers. All remaining lncRNAs were alaysed using 
the NormFinder algorithm [41] and ranked according 
to their stability values. Only lncRNAs with stability 
values of < 0.1 were considered as suitable normalis-
ers.  
We identified 24 lncRNAs suitable as normalis-
ers in diffuse astrocytomas (Table 3, Figure 2A). The 
top five are Zfhx2as (stability value 0.008), H19 (sta-
bility value 0.010), EgoA (stability value 0.010), 
IGF2AS (stability value 0.010) and Hoxa11as (stability 
value 0.012). In case of anaplastic astrocytomas, we 
identified 22 suitable normalisers (Table 3, Figure 
2B), the five most stable lncRNAs are SNHG4 (stabil-
ity value 0.005), H19 upstream conserved 1 and 2 
(stability value 0.006), Dio3os (stability value 0.010), 
Hoxa11as (stability value 0.011) and IGF2AS (stability 
value 0.013). In glioblastoma we identified 12 suitable 
lncRNAs (Table 3, Figure 2C), the top five are LUST 
(stability value 0.016), SNHG4 (stability value 0.019), 
EgoA (stability value 0.034), H19 upstream conserved 
1 and 2 (stability value 0.035) and EGO B (stability 
value 0.036). 
Table 3. Stably expressed lncRNAs in single glioma entities. We identified 24 suitable normalisers in diffuse astrocytoma (WHO-Grade 
II), 22 suitable normalisers in anaplastic astrocytoma (WHO-grade III) and 12 suitable normalisers in glioblastoma (WHO-Grade IV). All 
lncRNAs are arranged according to their stability values. Stability values are calculated using the NormFinder algorithm. 
Diffuse Astrocytoma (WHO-Grade II) Anaplastic Astrocytoma (WHO-Grade III) Glioblastoma (WHO-Grade IV) 
Gene name Stability value Standard error Gene name Stability value Standard error Gene name Stability value Standard error 
Zfhx2as 0.008 0.004 SNHG4 0.005 0.004 LUST 0.016 0.005 
H19 0.010 0.004 H19 ups. cons. 1, 2 0.006 0.004 SNHG4 0.019 0.005 
EgoA 0.010 0.004 Dio3os (family) 0.010 0.005 EgoA 0.034 0.007 
IGF2AS (family) 0.010 0.004 Hoxa11as 0.011 0.005 H19 ups. cons. 1, 2 0.035 0.008 
Hoxa11as 0.012 0.005 IGF2AS (family) 0.013 0.005 EGO B 0.036 0.008 
SNHG4 0.013 0.005 HOXA6as 0.013 0.005 Zfhx2as 0.041 0.009 
ST7OT 0.015 0.006 H19 0.013 0.006 ncR-uPAR 0.045 0.009 
HOTAIRM1 0.015 0.006 HAR1A 0.013 0.006 21A 0.048 0.010 
Nespas 0.016 0.006 H19 antisense 0.014 0.006 HOXA6as 0.051 0.010 
21A 0.017 0.006 LUST 0.016 0.006 GAS5-family 0.065 0.013 
H19 antisense 0.018 0.007 Air 0.017 0.007 NDM29 0.067 0.013 
snaR 0.018 0.007 21A 0.019 0.007 BC200 0.086 0.017 
Tsix 0.019 0.007 CAR Intergenic 10 0.020 0.008       
Dio3os (family) 0.019 0.007 ncR-uPAR 0.024 0.009       
EGO B 0.021 0.008 GAS5-family 0.025 0.009       
LUST 0.025 0.009 EgoA 0.027 0.010       
HOXA6as 0.025 0.009 HOTAIRM1 0.029 0.011       
lincRNA-p21 0.026 0.009 EGO B 0.030 0.011       
GAS5-family 0.027 0.010 BC200 0.034 0.012       
H19 ups. cons. 1, 2 0.029 0.010 Zfhx2as 0.037 0.013       
ncR-uPAR 0.029 0.010 Tsix 0.053 0.019       
NEAT1 (family) 0.030 0.011 NDM29 0.069 0.025       
BC200 0.042 0.015             
NDM29 0.045 0.016             
 





Figure 2. Identification of stable lncRNAs in diffuse astrocytoma in different glioma entities. In diffuse astrocytoma (WHO-Grade II) we identified 24 (A), in anaplastic 




Table 4. Stably expressed lncRNAs suitable for studies in different human glioma entities. We identified 7 lncRNAs that are suitable for 
studies in multiple glioma entities. All lncRNAs are arranged according to their stability values. Intragroup and intergroup variations 
indicated were calculated using the NormFinder algorithm.  
Glioma Intragroup variation Intergroup variation 
Gene name Stability value A II A III GBM A II A III GBM 
Zfhx2as 0.014 0.000 0.001 0.001 0.000 -0.006 0.005 
SNHG4 0.017 0.001 0.000 0.001 -0.013 0.001 0.013 
HOXA6as 0.018 0.001 0.000 0.004 0.002 0.005 -0.007 
H19 ups. cons. 1, 2 0.019 0.000 0.000 0.002 -0.017 0.004 0.013 
ncR-uPAR 0.024 0.001 0.000 0.001 -0.004 0.023 -0.019 
21A 0.025 0.000 0.000 0.002 0.005 -0.027 0.021 
BC200 0.029 0.001 0.001 0.007 0.027 0.000 -0.027 
 
 
Expression stability of lncRNA references 
suitable for comparison of gliomas and normal 
brain tissue 
To investigate gliomas during malignant trans-
formation it is important to perform longitudinally 
designed studies that include tumour specimen be-
fore and after malignant transformation. To identify 
lncRNA normalisers that are applicable for diffuse 
astrocytoma, anaplastic astrocytoma and glioblasto-
ma, we applied an extended bioinformatical ap-
proach: (1) Exclusion of low abundant lncRNAs with 
Ct values of ≥ 30, (2) exclusion of all lncRNAs with 
stability values of ≥ 0.1 in NormFinder analysis and 
(3) exclusion of all lncRNAs with significantly differ-
ent expression levels (p < 0.05) in significance testing 
in order to consider both intragroup and intergroup 
variations during selection process. 
We identified 7 lncRNAs that fulfilled all criteria 
to be considered as stably expressed in all investi-
gated tumour entities (Table 4, Figure 3). The five 
most stable lncRNAs are Zfhx2as (stability value 
0.014), SNHG4 (stability value 0.017), HOXA6as (sta-
bility value 0.018), H19 upstream conserved 1 and 2 
(stability value 0.019) and ncR-uPAR (stability value 
0.024). 
To identify lncRNAs being suitable as normalis-
ers in different glioma entities and in normal brain 
tissue, we further enhanced our analysis by adding 
expression data of normal white matter. We applied 
the similar approach as in case of multiple glioma 
entities and found four stably expressed lncRNAs 
(Table 5, Figure 4): HOXA6as (stability value 0.019), 
H19 upstream conserved 1 and 2 (stability value 
0.024), Zfhx2as (stability value 0.030) and BC200 (sta-
bility value 0.044). These lncRNAs may be regarded as 
universal normalisers being applicable in a broad 
range of studies focussing on human glioma research. 





Figure 3. Stably expressed lncRNAs suitable for studies comparing different 
glioma entities. We identified 7 lncRNAs that are suitable as normalisers in 
studies investigating different glioma entities. Indicated are mean and SD. 
 
 
Figure 4. Identification of lncRNAs suitable as normalisers in studies investi-
gating glioma and normal brain tissue. We identified 4 lncRNAs that show stable 
expression in different glioma entities and in normal white matter. These 
normalisers can be regarded as universal normalisers that are suitable as 
references in a broad range of lncRNA studies. Indicated are mean and SD. 
 
Table 5. Stably expressed lncRNAs suitable for studies in human gliomas and normal brain tissue. We identified 4 lncRNAs that show 
stable expression levels in all three glioma entities and in normal occipital white matter. These lncRNAs may be regarded as universal 
normalisers applicable in a broad range of lncRNA studies. All lncRNAs are arranged according to their stability values. Intragroup and 
intergroup variations indicated were calculated using the NormFinder algorithm. 
Glioma and white matter Intragroup variation Intergroup variation 
Gene name Stability value A II A III GBM WM A II A III GBM WM 
HOXA6as 0.019 0.001 0.000 0.003 0.001 -0.002 0.003 -0.004 0.002 
H19 ups. cons. 1, 2 0.024 0.000 0.000 0.002 0.001 -0.025 -0.002 0.012 0.014 
Zfhx2as 0.030 0.000 0.002 0.001 0.000 -0.015 -0.020 -0.003 0.038 




Recently it has been found that mRNA repre-
sents only a small fraction of RNA as the vast majority 
of DNA is transcribed into RNAs. In this context, 
lncRNAs are of emerging importance as there is in-
creasing evidence that lncRNAs are of regulatory sig-
nificance in numerous cellular processes [1, 4-7]. Since 
conscious quantifications of lncRNAs need adequate, 
reliable normalisation strategies, it is important to 
perform systematic evaluations of potential normal-
isers [42, 43].  
The current study is the first systematic analysis 
of a wide range of lncRNAs in gliomas of different 
WHO-Grades (diffuse astrocytoma WHO-Grade II, 
anaplastic astrocytoma WHO-Grade III, glioblastoma 
WHO-Grade IV) as well as normal white matter using 
quantitative PCR (qPCR) to identify suitable normal-
isers allowing both longitudinal studies of gliomas 
before and after malignant transformation and studies 
comparing glioma and normal brain tissue. Investi-
gating 90 lncRNAs being annotated in the lncRNA 
database [9] we were able to detect suitable references 
for the different tumour entities both alone and in 
comparison with each other. Of the 90 lncRNAs we 
identified 24 suitable normalisers in diffuse astrocy-
tomas, 22 in anaplastic astrocytomas and 12 in glio-
blastomas. Interestingly, we found that glioblastoma 
showed the lowest number of stably expressed 
lncRNAs. Applying a rigorous bioinformatical ap-
proach, the number of suitable normalisers was dra-
matically reduced by comparing expression levels 
across all three glioma entities: We identified 7 suita-
ble normalisers for studies comparing different glio-
ma entities (i.e. Zfhx2as, SNHG4, HOXA6as, H19 up-
stream conserved 1 and 2, ncR-uPAR, 21A and 
BC200). These normalisers are suitable for e.g. longi-
tudinal studies of gliomas before and after malignant 
transformation. Interestingly, even highly ranked in 
single tumour entities many lncRNAs turned out to be 
unsuitable as normalisers across tumour subgroups as 
being differentially expressed in different entities and 




thus not being suitable as proper intergroup normal-
isers. The addition of normal white matter resulted in 
only 4 suitable normalisers: HOXA6as, H19 upstream 
conserved 1 and 2, Zfhx2as and BC200. Thus, these 4 
normalisers may be regarded as universal normalisers 
suitable for a broad range of lncRNA studies. SNHG4, 
ncR-uPAR and 21A showed to be differentially ex-
pressed in glioma and normal white matter being 
unsuitable as normalisers comparing normal tissue 
and glioma. As recent publications show that nor-
malisation to a single reference gene is not sufficient, 
even if normalisers were identified in a conscious 
way, the optimal normalisation strategy should in-
clude at least a combination of two or more references 
[37, 44, 45]. Thus, we suggest a combination of all 4 
universal normalisers in lncRNA studies. This strat-
egy will further increase the reproducibility and va-
lidity of lncRNA studies in glioma and normal brain 
tissue.  
In summary, we showed that the proper selec-
tion of normalisers is an absolute requirement for 
valid determination of lncRNA expression profiles 
using quantitative PCR. Only by selecting proper 
normalisers, valid and reproducible data can be gen-
erated. We identified a set of 4 normalisers applicable 
as references for accurate lncRNA studies in human 
diffuse astrocytoma (WHO-Grade II), anaplastic as-
trocytoma (WHO-grade III), glioblastoma 
(WHO-Grade IV) and normal white matter tissue. A 
combination of these 4 normalisers will result in un-
biased results. Thus, the data presented in this study 
will further boost research on lncRNAs in human 
gliomas and allows even longitudinal studies of gli-
omas during malignant transformation and tumour 
progression.  
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